FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Assessing a biomarker platform for stratifying indeterminate pulmonary nodules, protocol for the SPOT IT randomized trial. PMID 42121244 · Trials · 2026-May-12 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Intravenous Patient-Controlled Analgesia Versus Oral Opioids to Maintain Analgesia for Severe Cancer Pain: A Randomized Phase III Trial. PMID 42119607 · J Natl Compr Canc Netw · 2026-May-12 The study is a randomized Phase III trial with a drug intervention (hydromorphone vs. morphine) in oncology patients. However, the primary efficacy endpoint is pain relief measured by the Numeric Rating Scale (NRS), which is not a time-to-event outcome (e.g., OS, PFS, DFS). No Kaplan-Meier curves or hazard ratios for time-to-event endpoints are reported. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Preoperative Stereotactic Body Radiotherapy for Metastatic Bone Disease With Impending Fracture: A Nonrandomized Clinical Trial. PMID 42119606 · J Natl Compr Canc Netw · 2026-May-12 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Risk-Benefit of Phase 2 Monotherapy Trials in Adult Solid Cancers: A Systematic Review and Meta-Analysis. PMID 42117884 · Int J Cancer · 2026-May-12 The record is a systematic review and meta-analysis comparing phase 2 and phase 3 trials, not an original report of a single randomized trial. It does not meet the criteria for a drug-containing intervention trial with a primary/key secondary time-to-event endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Biochemical Recurrence Irradiation or Observation (BRIO) in patients with prostate cancer: protocol for a randomised control trial. PMID 42117295 · BJU Int · 2026-May-12 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Cardioprotective effects of platycodon grandiflorum granules in HER2-positive early breast cancer patients receiving trastuzumab plus pertuzumab: study protocol for a double blind randomized controlled trial. PMID 42116119 · BMC Complement Med Ther · 2026-May-12 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Intrawound Tobramycin Plus Vancomycin to Prevent Surgical Site Infection in Tibial Fractures: The TOBRA Randomized Clinical Trial. PMID 41984450 · JAMA · 2026-May-12 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Single-Pill Low-Dose Triple Combination Therapy vs Standard-Dose Monotherapy in Patients With Mild-to-Moderate Hypertension. PMID 41670573 · J Am Coll Cardiol · 2026-May-12 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Shen-Ling-Lian-Xia Granule Combined With Neoadjuvant Chemotherapy in Patients With Triple-Negative Breast Cancer: Protocol for a Randomized, Double-Blind, Multicenter Clinical Trial. PMID 42219932 · JMIR Res Protoc · 2026-May-11 The record is a protocol for a randomized trial but does not report original results and uses a non-time-to-event primary endpoint. It is excluded as a protocol-without-results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Encounter tool for Shared Decision Making about Adjuvant Treatment of Lung Cancer: Randomized Clinical Trial. PMID 42183367 · Res Sq · 2026-May-11 The record describes a planned randomized trial protocol for evaluating a shared decision-making tool, not a report of trial results. It lacks a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The phase is not definitively established as Phase III/IIIb or Phase II/III. Therefore, it does not meet the eligibility criteria for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Segmentectomy Versus Lobectomy in NSCLC With Pathologically Invasive Features: A Post Hoc Supplementary Analysis of Multicenter, Phase 3 Trial JCOG0802/WJOG4607L. PMID 42119729 · J Thorac Oncol · 2026-May-11 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Elagolix Versus Dienogest for Treatment of Moderate-to-Severe Endometriosis Pain: A Phase III, Multicentric, Double-Blind, Active-Controlled, Non-Inferiority Study. PMID 42116589 · BJOG · 2026-May-11 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effects of digital exercise therapy and cognitive behavioral therapy on body image and social distance of postoperative patients with breast cancer: study protocol for a randomized controlled trial. PMID 42116180 · Trials · 2026-May-11 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Involved nodal versus elective neck radiotherapy (INVERT) for head and neck squamous cell carcinoma: a prospective phase II randomized controlled trial protocol. PMID 42116021 · BMC Cancer · 2026-May-11 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Phase 2 study of talabostat, a small molecule inhibitor of dipeptidyl peptidases (DPP), administered in combination with pembrolizumab in patients with small cell neuroendocrine prostate cancer. PMID 42114950 · J Immunother Cancer · 2026-May-11 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Electronic symptom monitoring of patient-reported outcomes among patients with hepatocellular carcinoma during immunotherapy (PRIME-HCC): protocol for a randomised controlled trial. PMID 42114858 · BMJ Open · 2026-May-11 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Optimising a behavioural intervention to support endocrine therapy adherence for women with breast cancer: protocol for the ROSETA optimisation factorial randomised controlled trial. PMID 42108483 · Trials · 2026-May-11 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Discrepancies in Inter-Rater Agreement on Resectability of Recurrent Glioblastoma: Complementary Post-hoc Analysis of the Prospective, Randomized DIRECTOR Trial. PMID 42108589 · Neuro Oncol · 2026-May-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide. PMID 41894648 · J Clin Oncol · 2026-May-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Systemic Therapies for Desmoid Tumors: A Review of Past, Present, and Future Treatments. PMID 42192882 · Cancers (Basel) · 2026-May-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of simenafil in men with erectile dysfunction: a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group, phase 2 trial. PMID 42114123 · J Sex Med · 2026-May-09 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Suicidal Ideation Effectiveness and Safety Outcomes from the Ketamine for Adult Depression Study (KADS). PMID 42105367 · Arch Suicide Res · 2026-May-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Intraoperative biodegradable stent placement to reduce complications after pancreatoduodenectomy - interim results from a randomised clinical trial. PMID 42104174 · Langenbecks Arch Surg · 2026-May-09 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Long-term effects of colonoscopy screening on colorectal cancer incidence and mortality: a multicountry, population-based randomised controlled trial. PMID 42102826 · Lancet · 2026-May-09 The study is a randomized, Phase III trial in oncology with original results, but it is excluded because it does not involve a drug-containing intervention (colonoscopy is a screening procedure) and does not have a primary or key secondary time-to-event efficacy endpoint (outcomes are cumulative incidence and mortality risk ratios, not time-to-event analyses like OS, PFS, DFS, EFS, RFS, or TTP, and no Kaplan-Meier or HR is reported). |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Understanding randomized controlled trial generalizability through an embedded molecular diagnostics trial. PMID 42026952 · JNCI Cancer Spectr · 2026-May-09 The study is a randomized controlled trial (RCT) embedded within a genomic diagnostics trial for prostate cancer, but it is not a drug-intervention trial. It compares treatment patterns (secondary treatment rates and time to treatment) between trial participants and real-world cohorts, but the intervention is a genomic classifier, not a drug. The time-to-event endpoint is time to secondary treatment, but this is not a standard efficacy endpoint (e.g., OS, PFS, DFS) for a drug-containing intervention. The phase is not established as Phase III/IIIb or Phase II/III. Therefore, it does not meet the eligibility criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Placebo Response in Phase II-III Symptom Intervention Studies: A Focus on Chemotherapy-Induced Peripheral Neuropathy and Associated Neuropathic Pain. PMID 42192875 · Cancers (Basel) · 2026-May-08 The record describes a meta-analysis and pooled analysis of placebo response rates in multiple trials, not the primary results of a single Phase III randomized trial with a time-to-event efficacy endpoint. The study focuses on symptom outcomes (neuropathy response rates) and does not report OS, PFS, DFS, EFS, RFS, TTP, or Kaplan-Meier/HR analyses. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The convenience of contrast-enhanced intraoperative ultrasonic cholangiography in liver resection: a study protocol for a randomized, prospective, off-label trial. PMID 42104300 · BMC Surg · 2026-May-08 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Efsubaglutide alfa added to metformin improves glycaemia with β-cell functional responses in type 2 diabetes: a randomised, double-blind, placebo-controlled, two-stage adaptive phase 2b/3 trial (SUPER 2). PMID 42103705 · Nat Commun · 2026-May-08 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Tocilizumab Biosimilars versus Reference Tocilizumab in Rheumatoid Arthritis: A Meta-Analysis of Pharmacokinetic Biosimilarity, Efficacy, Safety, and Immunogenicity. PMID 42102037 · Pharmacology · 2026-May-08 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A Noddings' caring theory-based intervention to enhance coping with death competence in advanced lung cancer patients: a randomized controlled trial. PMID 42101688 · Support Care Cancer · 2026-May-08 Eligibility fails due to the absence of a drug intervention and a time-to-event efficacy endpoint. The study is a randomized trial in advanced lung cancer, but the intervention is non-pharmacological, and outcomes are psychological, not tumor-related time-to-event endpoints like OS or PFS. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Sequential versus upfront oxaliplatin-based therapy in metastatic colorectal cancer: long-term outcomes of a randomized phase 3 trial. PMID 42098284 · Commun Med (Lond) · 2026-May-08 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial. PMID 42098105 · Nat Commun · 2026-May-08 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Smoldering Multiple Myeloma: Early Intervention or Structured Surveillance? A Comprehensive Review of Evidence for and Against Early Therapy. PMID 42192867 · Cancers (Basel) · 2026-May-07 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Existential distress in advanced cancer: study protocol of a pragmatic randomized controlled trial of a short-term psychodynamic therapy (ORPHYS) compared to usual psycho-oncological treatment (TAU). PMID 42098804 · Trials · 2026-May-07 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Comparing keystone and Limberg flaps for pilonidal sinus: Does flap choice influence patient satisfaction? PMID 42098544 · Tech Coloproctol · 2026-May-07 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions (DESTINATION 2): protocol for a randomised, phase II/R-IDEAL2b trial. PMID 42097645 · BMJ Open · 2026-May-07 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Low-frequency rTMS in combination with nicotine replacement therapy for smoking cessation: a phase II non-comparative Fleming-type randomized, double-blind, sham-controlled trial. PMID 42096636 · Nicotine Tob Res · 2026-May-07 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Optimizing bone health in lymphoma survivors: denosumab superiority to alendronate for R-CHOP-like therapy (the DENOSULY phase III randomized controlled trial). PMID 42095246 · Haematologica · 2026-May-07 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
B
|
影子组漏检补回 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Efficacy and safety of Brivaracetam as an adjunctive therapy in patients with focal-onset seizures: a phase III, multi-center, randomized, double-blind, placebo-controlled trial. PMID 42092987 · Acta Epileptol · 2026-May-07 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Combined Oral Ivermectin and 5% Permethrin Cream to Treat Severe Scabies. PMID 42090793 · N Engl J Med · 2026-May-07 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults. PMID 42090792 · N Engl J Med · 2026-May-07 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Left Ventricular Unloading in High-Risk Percutaneous Coronary Intervention. PMID 41910380 · N Engl J Med · 2026-May-07 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A randomized controlled trial of metastasis-directed therapy for oligometastases in breast cancer: OLIGAMI trial (JCOG2110). PMID 41615067 · Jpn J Clin Oncol · 2026-May-07 The record describes a randomized controlled trial protocol for a Phase III (implied by the question of superiority) study of metastasis-directed therapy plus systemic drug therapy versus systemic drug therapy alone for oligometastatic breast cancer, with overall survival as the primary endpoint. However, it is a protocol abstract without reported results, the phase is not explicitly stated as Phase III/IIIb or Phase II/III, and while systemic drug therapy is part of the intervention, it is not specified as a drug-containing intervention in a way that can be confirmed from the abstract alone (it could be non-drug therapy). Therefore, it does not meet the criteria for an original formal-result report of a randomized trial with a drug-containing intervention. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Long-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemia. PMID 41525466 · Blood · 2026-May-07 The study reports on a gene therapy for transfusion-dependent β-thalassemia, a hematologic disorder but not a malignant neoplasm. The primary efficacy outcomes are transfusion independence and hemoglobin levels, which are not time-to-event endpoints like OS, PFS, or DFS. While the study includes a phase 3 component and reports long-term efficacy results, it fails the fundamental oncology criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): A systematic review and meta-analysis. PMID 42275677 · Am J Surg · 2026-May-06 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial. PMID 42105781 · Lancet HIV · 2026-May-06 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Event rates in major Phase 3 heart failure trials over the last 20 years. PMID 42275607 · ESC Heart Fail · 2026-May-05 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Survival outcomes in POD1UM-303/InterAACT-2: a phase 3 study of retifanlimab plus carboplatin-paclitaxel in first-line advanced squamous anal cancer. PMID 42097353 · Ann Oncol · 2026-May-05 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Clobetasol Propionate Ophthalmic Suspension to Treat Ocular Inflammation and Pain after Uncomplicated Cataract Surgery. PMID 42097332 · Ophthalmology · 2026-May-05 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Fragility Analysis of Cardiovascular Outcomes with Finerenone in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. PMID 42087276 · Eur J Heart Fail · 2026-May-05 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |